Barr Pharmaceuticals Inc. announced that its subsidiary, Barr Laboratories Inc., has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) to manufacture and market a generic version of Yasmin (drospirenone and ethinyl estradiol). Yasmin is an oral contraceptive product manufactured and marketed by Bayer Schering Pharma AG.

Teva Pharmaceutical Industries Ltd. has received tentative FDA approval for its ANDA (abbreviated new drug application) to market a gastric-acid pump inhibitor. Teva is currently in patent dispute litigation over the product, which is a generic form of TAP Pharmaceutical’s drug Prevacid (Lansoprazole) Delayed-release Capsules, 15 mg and 30 mg.